| Year |
Citation |
Score |
| 2024 |
Jin Y, Miyama T, Brown A, Hayase T, Song X, Singh AK, Huang L, Flores II, McDaniel LK, Glover I, Halsey TM, Prasad R, Chapa V, Ahmed S, Zhang J, ... ... Lizee G, et al. Tsyn-seq: a T cell synapse-based antigen identification platform. Cancer Immunology Research. PMID 38363296 DOI: 10.1158/2326-6066.CIR-23-0467 |
0.432 |
|
| 2024 |
Chaudhri A, Lizee G, Hwu P, Rai K. Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment. Cancer Research. PMID 38266066 DOI: 10.1158/0008-5472.CAN-23-2244 |
0.36 |
|
| 2023 |
Chaudhri A, Bu X, Wang Y, Gomez M, Torchia JA, Hua P, Hung SH, Davies MA, Lizee GA, von Andrian U, Hwu P, Freeman GJ. The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy. Frontiers in Immunology. 14: 1237715. PMID 37771579 DOI: 10.3389/fimmu.2023.1237715 |
0.387 |
|
| 2023 |
Hall-Swan S, Slone J, Rigo MM, Antunes DA, Lizée G, Kavraki LE. PepSim: T-cell cross-reactivity prediction via comparison of peptide sequence and peptide-HLA structure. Frontiers in Immunology. 14: 1108303. PMID 37187737 DOI: 10.3389/fimmu.2023.1108303 |
0.471 |
|
| 2023 |
Liang S, Jiang X, Chiu Y, Xu H, Kim KH, Lizee G, Chen K. An interpretable ML model to characterize patient-specific HLA-I antigen presentation. Biorxiv : the Preprint Server For Biology. PMID 36993682 DOI: 10.1101/2023.03.12.532264 |
0.34 |
|
| 2022 |
Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, ... ... Lizee G, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 40: 509-523.e6. PMID 35537412 DOI: 10.1016/j.ccell.2022.04.004 |
0.421 |
|
| 2021 |
Sun Y, Li F, Sonnemann H, Jackson KR, Talukder AH, Katailiha AS, Lizee G. Evolution of CD8 T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer. Cells. 10. PMID 34572028 DOI: 10.3390/cells10092379 |
0.508 |
|
| 2021 |
Li F, Deng L, Jackson KR, Talukder AH, Katailiha AS, Bradley SD, Zou Q, Chen C, Huo C, Chiu Y, Stair M, Feng W, Bagaev A, Kotlov N, Svekolkin V, ... ... Lizee G, et al. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. Journal For Immunotherapy of Cancer. 9. PMID 34244308 DOI: 10.1136/jitc-2021-002531 |
0.44 |
|
| 2021 |
Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Lizée G, Wong MK, McQuade JL, et al. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. Journal For Immunotherapy of Cancer. 9. PMID 34021033 DOI: 10.1136/jitc-2021-002449 |
0.507 |
|
| 2021 |
Yoshihama S, Cho SX, Yeung J, Pan X, Lizee G, Konganti K, Johnson VE, Kobayashi KS. NLRC5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. Scientific Reports. 11: 3258. PMID 33547395 DOI: 10.1038/s41598-021-82729-9 |
0.354 |
|
| 2020 |
Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, et al. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nature Communications. 11: 5332. PMID 33087697 DOI: 10.1038/s41467-020-19141-w |
0.403 |
|
| 2020 |
Phillips S, Lizee G, Brown C, Lara JM, Bassett RL, Beal LG, Murthy R, Talukder A, Hawke DH, Lai I, Hwu P, Yee C, Patel SP. A phase Ib study of endogenous SLC45A2-specific cytotoxic T cells for the treatment of patients with metastatic uveal melanoma. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps10086 |
0.354 |
|
| 2019 |
Peng W, Williams LJ, Xu C, Melendez B, McKenzie JA, Chen Y, Jackson H, Voo KS, Mbofung RM, Leahey SE, Wang J, Lizee G, Tawbi HA, Davies MA, Hoos A, et al. Anti-OX40 antibody directly enhances the function of tumor-reactive CD8 T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31371342 DOI: 10.1158/1078-0432.Ccr-19-1259 |
0.54 |
|
| 2019 |
Nusrat M, Roszik J, Katkhuda R, Menter D, Raghav KPS, Morris VK, Sharma P, Allison JP, Blando JM, Maru DM, Lizee G, Janku F, Overman MJ, Kopetz S. Association of PIK3CA mutations (mut) with immune engagement and clinical benefit from immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC) patients (pts). Journal of Clinical Oncology. 37: 3604-3604. DOI: 10.1200/Jco.2019.37.15_Suppl.3604 |
0.414 |
|
| 2018 |
Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, ... ... Lizee G, et al. Dynamic changes during the treatment of pancreatic cancer. Oncotarget. 9: 14764-14790. PMID 29599906 DOI: 10.18632/Oncotarget.24483 |
0.478 |
|
| 2018 |
Antunes DA, Devaurs D, Moll M, Lizée G, Kavraki LE. General Prediction of Peptide-MHC Binding Modes Using Incremental Docking: A Proof of Concept. Scientific Reports. 8: 4327. PMID 29531253 DOI: 10.1038/S41598-018-22173-4 |
0.384 |
|
| 2018 |
Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets TV, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung R, Wang ZQ, Davis RE, Lo RS, ... ... Lizee G, et al. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29496759 DOI: 10.1158/1078-0432.Ccr-17-2483 |
0.31 |
|
| 2018 |
Sakellariou-Thompson D, Forget M, Roszik J, Jackson KR, Kim YU, Crosby S, Hurd MW, Wu J, Jiang Z, Hwu P, Lizee G, Menter D, Kopetz S, Overman MJ, Haymaker CL, et al. Preclinical development of tumor-infiltrating lymphocyte therapy for metastatic colorectal cancer. Journal of Clinical Oncology. 36: 95-95. DOI: 10.1200/Jco.2018.36.5_Suppl.95 |
0.545 |
|
| 2017 |
Lyons YA, Pradeep S, Wu SY, Haemmerle M, Hansen JM, Wagner MJ, Villar-Prados A, Nagaraja AS, Dood RL, Previs RA, Hu W, Zhao Y, Mak DH, Xiao Z, Melendez BD, ... Lizee GA, et al. Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 8: 96496-96505. PMID 29228548 DOI: 10.18632/Oncotarget.20410 |
0.352 |
|
| 2017 |
Antunes DA, Rigo MM, Freitas MV, Mendes MFA, Sinigaglia M, Lizée G, Kavraki LE, Selin LK, Cornberg M, Vieira GF. Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy. Frontiers in Immunology. 8: 1210. PMID 29046675 DOI: 10.3389/Fimmu.2017.01210 |
0.527 |
|
| 2017 |
Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, ... ... Lizee G, et al. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nature Communications. 8: 451. PMID 28878208 DOI: 10.1038/S41467-017-00449-Z |
0.515 |
|
| 2017 |
Park J, Talukder AH, Lim S, Kim K, Pan K, Melendez B, Bradley SD, Jackson K, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, ... ... Lizee G, et al. SLC45A2: A melanoma antigen with high tumor selectivity and reduced potential for autoimmune toxicity. Cancer Immunology Research. PMID 28630054 DOI: 10.1158/2326-6066.Cir-17-0051 |
0.551 |
|
| 2017 |
Yee C, Lizee GA. Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy. Cancer Journal (Sudbury, Mass.). 23: 144-148. PMID 28410303 DOI: 10.1097/Ppo.0000000000000255 |
0.584 |
|
| 2016 |
Li F, Chen C, Ju T, Gao J, Yan J, Wang P, Xu Q, Hwu P, Du X, Lizée G. Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. Oncoimmunology. 5: e1238539. PMID 28123873 DOI: 10.1080/2162402X.2016.1238539 |
0.443 |
|
| 2016 |
Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA, Kobayashi KS. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 27162338 DOI: 10.1073/Pnas.1602069113 |
0.473 |
|
| 2016 |
Bradley SD, Melendez B, Talukder A, Lizée G. Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression in melanoma. Oncoimmunology. 5: e1078966. PMID 27057458 DOI: 10.1080/2162402X.2015.1078966 |
0.561 |
|
| 2016 |
Bernatchez C, Cooper ZA, Wargo JA, Hwu P, Lizée G. Novel Treatments in Development for Melanoma. Cancer Treatment and Research. 167: 371-416. PMID 26601872 DOI: 10.1007/978-3-319-22539-5_16 |
0.384 |
|
| 2016 |
Sergeeva A, He H, Cox K, John LS, Sang M, Kerros C, Li Q, Herrmann A, Clise-Dwyer K, Ma Q, Lizee G, Alatrash G, Molldrem JJ. Humanized Anti-PR1/HLA-A2 T Cell Receptor-like Monoclonal Antibody, h8F4, Has Multiple Effector Mechanisms Blood. 128: 4061-4061. DOI: 10.1182/Blood.V128.22.4061.4061 |
0.39 |
|
| 2016 |
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff M, Xu C, McKenzie J, Zhang C, Liang X, Williams L, Deng W, Chen G, Mbofung R, Lazar A, et al. Abstract 4363: Loss of PTEN promotes resistance to T cell-mediated immunotherapy Cancer Research. 76: 4363-4363. DOI: 10.1158/1538-7445.Am2016-4363 |
0.555 |
|
| 2015 |
Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, ... ... Lizee G, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discovery. PMID 26645196 DOI: 10.1158/2159-8290.Cd-15-0283 |
0.575 |
|
| 2015 |
Bradley SD, Chen Z, Melendez B, Talukder A, Khalili JS, Rodriguez-Cruz T, Liu S, Whittington M, Deng W, Li F, Bernatchez C, Radvanyi LG, Davies MA, Hwu P, Lizée G. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunology Research. 3: 602-9. PMID 25795007 DOI: 10.1158/2326-6066.Cir-15-0030 |
0.586 |
|
| 2015 |
Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P. Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma. Sarcoma. 2015: 547460. PMID 25705114 DOI: 10.1155/2015/547460 |
0.538 |
|
| 2015 |
Hunsucker SA, McGary CS, Vincent BG, Enyenihi AA, Waugh JP, McKinnon KP, Bixby LM, Ropp PA, Coghill JM, Wood WA, Gabriel DA, Sarantopoulos S, Shea TC, Serody JS, Alatrash G, et al. Peptide/MHC tetramer-based sorting of CD8⁺ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoire. Cancer Immunology Research. 3: 228-35. PMID 25576336 DOI: 10.1158/2326-6066.Cir-14-0001 |
0.536 |
|
| 2014 |
Li F, Guo Z, Lizée G, Yu H, Wang H, Si T. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients. Clinical Chemistry and Laboratory Medicine : Cclm / Fescc. 52: 1357-65. PMID 24646790 DOI: 10.1515/Cclm-2013-0878 |
0.376 |
|
| 2013 |
Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, et al. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 276-86. PMID 23603862 DOI: 10.1097/Cji.0B013E31829419F3 |
0.435 |
|
| 2013 |
Khalili JS, Hwu P, Lizee GA. Forging a link between oncogenic signaling and immunosuppression in melanoma Oncoimmunology. 2. PMID 23525189 DOI: 10.4161/Onci.22745 |
0.547 |
|
| 2013 |
Yang Y, Lizee GA, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with immunotherapy Oncoimmunology. 2. PMID 23524978 DOI: 10.4161/Onci.22730 |
0.416 |
|
| 2013 |
Peng W, Lizee GA, Hwu P. Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer. Oncoimmunology. 2. PMID 23524510 DOI: 10.4161/Onci.22691 |
0.492 |
|
| 2013 |
Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, Sergeeva A, Ruisaard K, Al-Atrache Z, Ropp PA, Jakher H, Rodriguez-Cruz T, Lizee G, Clise-Dwyer K, Lu S, et al. A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 247-57. PMID 23147993 DOI: 10.1158/1078-0432.Ccr-12-2753 |
0.453 |
|
| 2013 |
Lizée G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annual Review of Medicine. 64: 71-90. PMID 23092383 DOI: 10.1146/Annurev-Med-112311-083918 |
0.42 |
|
| 2012 |
Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 6758-70. PMID 23032743 DOI: 10.1158/1078-0432.Ccr-12-1177 |
0.457 |
|
| 2012 |
Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, Woodman SE, Hwu P. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 120: 4533-43. PMID 22936666 DOI: 10.1182/Blood-2012-02-407163 |
0.599 |
|
| 2012 |
Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizée G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Research. 72: 5209-18. PMID 22915761 DOI: 10.1158/0008-5472.Can-12-1187 |
0.511 |
|
| 2012 |
Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, Esmaeli B, Woodman SE. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4345-55. PMID 22733540 DOI: 10.1158/1078-0432.Ccr-11-3227 |
0.33 |
|
| 2012 |
Alatrash G, Ono Y, Sergeeva A, Sukhumalchandra P, Zhang M, St John LS, Yang TH, Ruisaard K, Armistead PM, Mittendorf EA, He H, Qiao N, Rodriguez-Cruz T, Liang S, Clise-Dwyer K, ... ... Lizee G, et al. The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 309-20. PMID 22495388 DOI: 10.1097/Cji.0B013E31824B3B14 |
0.301 |
|
| 2012 |
Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizée G, Zhou D, Overwijk WW, Hwu P. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. Journal of Immunotherapy (Hagerstown, Md. : 1997). 35: 276-82. PMID 22421945 DOI: 10.1097/Cji.0B013E31824E7F43 |
0.49 |
|
| 2012 |
Hong DS, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R, Lizee G, Hwu P. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2326-35. PMID 22355009 DOI: 10.1158/1078-0432.Ccr-11-2515 |
0.464 |
|
| 2012 |
Wu RC, Liu S, Chacon JA, Wu S, Li Y, Sukhumalchandra P, Murray JL, Molldrem JJ, Hwu P, Pircher H, Lizée G, Radvanyi LG. Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2465-77. PMID 22307139 DOI: 10.1158/1078-0432.Ccr-11-2034 |
0.541 |
|
| 2012 |
Lizée G, Liu C, Hwu P. Abstract PL03-03: The rational combination of BRAF inhibition with immunotherapy for the treatment of metastatic melanoma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Pl03-03 |
0.589 |
|
| 2012 |
Peng W, Liu C, Xu C, Chen J, Lou Y, Overwijk W, Lizée G, Yagita H, Hwu P. Abstract 4385: PD-1 blockade enhances T-cell migration to tumor through induction of IFN-γ inducible chemokines Cancer Research. 72: 4385-4385. DOI: 10.1158/1538-7445.Am2012-4385 |
0.508 |
|
| 2011 |
Rodríguez-Cruz TG, Liu S, Khalili JS, Whittington M, Zhang M, Overwijk W, Lizée G. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8+ T-cell responses and boosts anti-tumor immunity. Plos One. 6: e22939. PMID 21860662 DOI: 10.1371/Journal.Pone.0022939 |
0.552 |
|
| 2011 |
Lou Y, Liu C, Lizée G, Peng W, Xu C, Ye Y, Rabinovich BA, Hailemichael Y, Gelbard A, Zhou D, Overwijk WW, Hwu P. Antitumor activity mediated by CpG: the route of administration is critical. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 279-88. PMID 21389870 DOI: 10.1097/Cji.0B013E31820D2A05 |
0.571 |
|
| 2011 |
McGary C, Enyenihi AA, Hunsucker SA, Ropp PA, Rodriguez-Cruz T, Lizee G, Alatrash G, Glish GL, Armistead PM. Identification of Leukemia Associated Antigens From ANKRD17 and CDK4 Using Mass Spectrometry Based Screening, Blood. 118: 4020-4020. DOI: 10.1182/Blood.V118.21.4020.4020 |
0.542 |
|
| 2011 |
Zhang M, Sukhumalchandra P, Enyenihi AA, St. John LS, Hunsucker SA, Ruisaard K, Atrache ZA, Ropp PA, Rodriguez-Cruz T, Mittendorf E, Lizee G, Clise-Dwyer K, Lu S, Glish GL, Molldrem JJ, et al. A Novel HLA-A2 Restricted Peptide Derived From Cathepsin G Is An Effective Immunotherapeutic Target for Myeloid Leukemia Blood. 118: 2986-2986. DOI: 10.1182/Blood.V118.21.2986.2986 |
0.433 |
|
| 2010 |
Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, Whittington M, Yang Y, Overwijk WW, Lizée G, Hwu P. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5458-68. PMID 20889916 DOI: 10.1158/1078-0432.Ccr-10-0712 |
0.556 |
|
| 2010 |
Liu S, Etto TL, Rodriguez-Cruz T, Li Y, Wu C, Fulbright O, Hwu P, Radvanyi L, Lizee G. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy Journal of Immunotherapy. 33: 371-381. PMID 20386469 DOI: 10.1097/Cji.0B013E3181Cd1180 |
0.547 |
|
| 2010 |
Lizee G, Whittington MA, Chen J, Greene VR, Liu S, Bassett RL, Khalili J, Prieto V, Radvanyi LG, Hwu P, Grimm EA, Gershenwald JE. Correlation of prevalence of CD68+ macrophages within tumor-draining lymph node basins and overall survival in stage III melanoma patients. Journal of Clinical Oncology. 28: e21034-e21034. DOI: 10.1200/Jco.2010.28.15_Suppl.E21034 |
0.485 |
|
| 2008 |
Basha G, Lizée G, Reinicke AT, Seipp RP, Omilusik KD, Jefferies WA. MHC class I endosomal and lysosomal trafficking coincides with exogenous antigen loading in dendritic cells. Plos One. 3: e3247. PMID 18802471 DOI: 10.1371/Journal.Pone.0003247 |
0.688 |
|
| 2008 |
Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB. Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Research. 18: 241-5. PMID 18626307 DOI: 10.1097/Cmr.0B013E3283046146 |
0.331 |
|
| 2008 |
Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, Kim GJ, Wang YH, Ye Y, Sikora AG, Overwijk WW, Liu YJ, Wang G, Hwu P. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. The Journal of Clinical Investigation. 118: 1165-75. PMID 18259609 DOI: 10.1172/Jci33583 |
0.543 |
|
| 2007 |
Lee ST, Liu S, Radvanyi L, Sukhumalchandra P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizée G, Neelapu SS. A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. Journal of Immunological Methods. 331: 13-26. PMID 17959194 DOI: 10.1016/J.Jim.2007.09.006 |
0.583 |
|
| 2007 |
Zhu K, Qin H, Cha SC, Neelapu SS, Overwijk W, Lizee GA, Abbruzzese JL, Hwu P, Radvanyi L, Kwak LW, Chang DZ. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 25: 7955-61. PMID 17933439 DOI: 10.1016/J.Vaccine.2007.08.050 |
0.344 |
|
| 2007 |
Liu S, Lizée G, Lou Y, Liu C, Overwijk WW, Wang G, Hwu P. IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. International Immunology. 19: 1213-21. PMID 17898044 DOI: 10.1093/Intimm/Dxm093 |
0.389 |
|
| 2007 |
Lizee GA, Cantu MA, Hwu P. Less Yin, More Yang: Confronting the Barriers to Cancer Immunotherapy Clinical Cancer Research. 13: 5250-5255. PMID 17875752 DOI: 10.1158/1078-0432.Ccr-07-1722 |
0.591 |
|
| 2007 |
Zhu K, Lizee G, Cano P, Fernando-Vina M, Ji B, Abbruzzese JL, Hwu P, Radvanyi L, Chang DZ. HLA-A0201 positive pancreatic cell lines: new findings and discrepancies. Cancer Immunology, Immunotherapy : Cii. 56: 719-24. PMID 16947023 DOI: 10.1007/S00262-006-0217-8 |
0.434 |
|
| 2006 |
Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5801-8. PMID 17020987 DOI: 10.1158/1078-0432.Ccr-05-2421 |
0.586 |
|
| 2006 |
Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4794-803. PMID 16914564 DOI: 10.1158/1078-0432.Ccr-06-0944 |
0.582 |
|
| 2006 |
Lizée G, Radvanyi LG, Overwijk WW, Hwu P. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2359s-2365s. PMID 16609059 DOI: 10.1158/1078-0432.Ccr-05-2537 |
0.543 |
|
| 2006 |
Lee S, Liu S, Sukhumalchandra P, Molldrem J, Hwu P, Liu Y, Kwak LW, Lizee G, Neelapu SS. A Novel Strategy for Generation of Human Tumor-Specific T Cell Clones for Adoptive Transfer. Blood. 108: 3713-3713. DOI: 10.1182/Blood.V108.11.3713.3713 |
0.569 |
|
| 2005 |
Lizée G, Basha G, Jefferies WA. Tails of wonder: endocytic-sorting motifs key for exogenous antigen presentation. Trends in Immunology. 26: 141-9. PMID 15745856 DOI: 10.1016/J.It.2005.01.005 |
0.685 |
|
| 2004 |
Lou Y, Wang G, Lizée G, Kim GJ, Finkelstein SE, Feng C, Restifo NP, Hwu P. Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Research. 64: 6783-90. PMID 15374997 DOI: 10.1158/0008-5472.Can-04-1621 |
0.559 |
|
| 2004 |
Lizée G, Gonzales MI, Topalian SL. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Human Gene Therapy. 15: 393-404. PMID 15053864 DOI: 10.1089/104303404322959542 |
0.58 |
|
| 2004 |
Sharkey MS, Lizée G, Gonzales MI, Patel S, Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Research. 64: 1595-9. PMID 14996715 DOI: 10.1158/0008-5472.Can-03-3231 |
0.478 |
|
| 2003 |
Lizée G, Aerts JL, Gonzales MI, Chinnasamy N, Morgan RA, Topalian SL. Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Human Gene Therapy. 14: 497-507. PMID 12718761 DOI: 10.1089/104303403764539387 |
0.354 |
|
| Show low-probability matches. |